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Abstract
Melanoma is the most aggressive form of skin cancer, with fast progression and early dissemination mediated by the
melanoma inhibitory activity (MIA) protein. Here, we discovered that dimerization of MIA is required for functional activity
through mutagenesis of MIA which showed the correlation between dimerization and functional activity. We subsequently
identified the dodecapeptide AR71, which prevents MIA dimerization and thereby acts as a MIA inhibitor. Two-dimensional
nuclear magnetic resonance (NMR) spectroscopy demonstrated the binding of AR71 to the MIA dimerization domain, in
agreement with in vitro and in vivo data revealing reduced cell migration, reduced formation of metastases and increased
immune response after AR71 treatment. We believe AR71 is a lead structure for MIA inhibitors. More generally, inhibiting
MIA dimerization is a novel therapeutic concept in melanoma therapy.
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Introduction
MIA, an 11-kDa protein, was identified as strongly expressed
and secreted by melanocytic tumor cells, but not by benign
melanocytes [1]. MIA expression by melanoma cells correlates
strongly with a highly invasive phenotype and the ability to
metastasize [2,3]. Functionally, MIA binds to both extracellular
matrix proteins such as fibronectin, laminin and tenascin as well as
to specific integrins, cell surface proteins mediating cellular
attachment, and thereby contributes to tumor cell detachment
and invasion. MIA currently serves as a reliable clinical serum
tumor marker for the detection of metastatic diseases and for
monitoring responses to therapy [4]. A commercially available
MIA-ELISA is routinely used in the follow-up of melanoma
patients. Elevated serum levels of MIA correlate with metastatic
recurrence and poor prognosis.
The transport of MIA to the cell surface and subsequent
secretion is induced after migratory stimuli [5]. MIA then binds to
the cell adhesion receptors integrin a4b1 and integrin a5b1, which
enables tumor cells to invade healthy tissue, resulting in enhanced
metastatic potential [6]. In addition to supporting metastatic
spread, MIA has also been demonstrated to modulate immuno-
suppression. This effect is mediated by binding of MIA to integrin
a4b1 expressed by leukocytes [7].
The three-dimensional structure of MIA revealed that MIA
defines a novel type of secreted protein with an SH3-domain-like
fold [8]. Furthermore, the MIA homologues MIA2 and TANGO
have been found to share domains with a high sequence similarity
to MIA [9].
Results and Discussion
Previously, MIA was thought to act as a monomer; however,
Western blot analysis of melanoma tissue derived from a primary
tumor (PT) or metastases (Met) indicated that stable dimeric
species also exist in denaturating SDS-PAGE (Fig 1a). This
dimerization is obviously caused by a strong noncovalent
interaction since all four cysteins are bound in disulfide bridges
intramolecularly [8] which excludes the possibility of intermolec-
ular disulfide bridges. Using PreBI modeling software (http://pre-
s.protein.osaka-u.ac.jp/prebi/) to predict the putative dimer
interface and the HADDOCK protein-protein docking program
[10], we obtained a model of the MIA dimer that included a head-
to-tail linkage (Fig 1b). The dimerization interfaces are located
around the K53-L58 region in the n-Src loop and the cleft next to
Q65-A73 in the distal loop, as defined by the MIA 3D structure
[8]. The amino acid residues Y30, R55 and G61 were predicted
by these in silico studies to be particularly important for
dimerization. Interestingly, the same regions that we determined
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to form the interfaces were described as crucial for MIA activity in
a previous mutagenesis study [11]. We therefore investigated the
possible correlation between MIA dimerization and functional
activity. Having identified the most likely positions of the
dimerization interfaces, different mutants of MIA (D29G/Y69H,
V46F/S81P, T89P, K91N, G61R, Y30R and R55E) were tested
for their ability to form dimers by Western blot analysis (Fig 1c).
Wild-type (wt) MIA and all mutants except for G61R, Y30R and
R55E clearly showed a dimer band. As predicted, the mutations
affected the putative dimerization domains.
To correlate the functional activity of the different MIA mutants
with dimerization, Boyden chamber invasion assays were
performed with Mel-Im melanoma cells (Fig 1d). All mutations
preventing dimerization (Y30R, R55E, G61R) also led to a loss of
activity. The sites of the mutations that did not affect functional
MIA activity (Fig 1e, depicted in gray) are located outside the
dimerization regions, whereas Y30, R55 and G61 (Fig 1e,
depicted in magenta) are located in proximity to the dimerization
domains (red and blue). These results indicate that the MIA
binding site for extracellular matrix structures and integrins is only
formed upon dimerization. Interestingly, the amino acids required
for dimerization are highly conserved (Fig S1).
We further analyzed the MIA-homologous proteins MIA2 and
TANGO, two members of the MIA protein family [12]. Western
blotting demonstrated that these MIA homologues do not form
dimers (Fig 1f), which is in agreement with the sequence
alignment demonstrating that the amino acids crucial for
dimerization are not conserved in MIA2 and TANGO (Fig 1g).
Furthermore, the MIA dimerization domain in the n-Src loop
(K53-L58) shows an inversion of charge in MIA2 and TANGO.
The dimerization domain in the distal loop shows a large deletion
in MIA2 and TANGO, with Y68-R75 being absent in both of
these MIA homologues (Fig 1g).
To identify peptides inhibiting MIA dimerization, we applied a
newly developed heterogeneous transition-metal-based fluores-
cence polarization (HTFP) assay [13]. First, the MIA-MIA
interaction was confirmed using this assay. We immobilized a
MIA-biotin conjugate in a streptavidin-coated well plate and
added MIA labeled with the luminescent transition-metal complex
Ru(bpy)3. As depicted in Figure 2a, a significant increase in the
fluorescence polarization (FP) signal was observed in the wells
coated with MIA-biotin compared to control wells. This increase
was attributed to the severely restricted rotational mobility of
MIA-Ru(bpy)3 bound to the immobilized MIA-biotin. We then
screened peptides, previously identified by phage display and
known to generally bind to MIA [8], for their potential to prevent
MIA dimerization and to induce dissociation of already existing
protein dimers using the HTFP assay. The dodecapeptide AR71
(sequence: Ac-FHWRYPLPLPGQ-NH2) effectively dissociated
MIA dimers, which led to a decrease in FP due to increased
rotational diffusion of the dissociated monomeric MIA-Ru(bpy)3,
while other dodecapeptides (control peptides 1, sequence: Ac-
VSNYKFYSTTSS-NH2 and 2, sequence: Ac-YNLPKVSSNLSP-
NH2) did not affect the FP signal.
The inhibitory effect of AR71 on MIA dimerization was
confirmed by Western blot analysis (Fig 2b). Preincubation of
MIA with AR71 led to a strong reduction of the dimer band
compared to MIA without peptides or with MIA binding control
peptides 1 and 2. This inhibition of dimerization was also observed
in native PAGE experiments (Fig S2).
Boyden chamber invasion assays revealed that AR71 also
functionally inhibits MIA (Fig 2c). Preincubation of MIA with
AR71 resulted in complete neutralization of the effect of MIA on
melanoma cells. The results were confirmed in three other
melanoma cell lines (Mel-Ju, Mel-Wei, and Mel-Ho; data not
shown). We further tested AR71 in classical migration assays.
Significant inhibition of melanoma cell migration was observed
using two cell lines in three independent assays (Fig S1b). These
assays also indicated that AR71 does not induce apoptosis in vitro.
In line with the inhibitory effect of AR71 on the formation of
MIA aggregates, the direct binding of AR71 to the MIA
dimerization domain next to the distal loop was shown by
multidimensional NMR spectroscopy. By using increasing
amounts of AR71, the induced chemical shift changes of the
MIA 1HN and 15NH resonances were classified according to the
degree of the combined chemical shift perturbations. Further
analysis of the solvent accessibility (with a threshold of 20%) and
cluster analysis of the residues affected by peptide binding revealed
that the binding interface comprises residues C17, S18, Y47, G66,
D67, L76, W102, D103 and C106 in MIA (Fig 2d). These data
indicate that the peptide binds to the site depicted in red in
Figure 2d, whereas the opposite side of the molecule does not
participate in AR71 binding. The AR71 binding site is located in
the cleft next to the distal loop, where the G61R mutation leading
to functional inactivation is situated (Fig 1e). HTFP and Western
blot analyses confirmed the ability of AR71 to monomerize MIA
(Fig 2a and 2b). The concave nature of the AR71 binding site
makes it especially attractive as a druggable target due to its large
surface area and suitable geometry for binding small-molecule
pharmacophores that could be derived from AR71.
Next, we analyzed the interaction of AR71 with endogenous
MIA in B16 mouse melanoma cells stably transfected with a
secretion signal containing the AR71-HisTag construct (AR71-
HisTag). With the addition of an N-terminal secretion sequence
ensuring peptide processing in the endoplasmic reticulum, we
expected subsequent binding and thus inactivation of MIA directly
at the location of protein biosynthesis.
We first investigated the expression and localization of the
AR71-HisTag peptide by immunofluorescence analysis. Co-
staining of MIA and AR71-HisTag revealed co-localization in
close proximity to the nucleus (Fig 3a).
While no effect of AR71-HisTag on cell growth was observed,
functional in vitro analysis confirmed that migration is drastically
reduced in AR71-HisTag-expressing cell clones compared to
mock-transfected control cells (Fig 3b), and HTFP analysis
demonstrated that AR71-HisTag interferes with the MIA-MIA
interaction (data not shown).
Because in vivo studies have demonstrated the strong contribu-
tion of MIA to melanoma cell invasion and migration [14,15] we
aimed to assess the effect of AR71 on the metastasis of melanoma
cells and on the immune response in vivo. Therefore, we employed
an established syngeneic murine model of hepatic metastasis [16]
using the AR71-HisTag-containing cell clones. Notably, mice
injected with AR71-HisTag melanoma cell clones had significantly
fewer hepatic metastases than mice that received mock-transfected
control cells (Fig 3c and 3d).
Additionally, immunohistochemistry analysis revealed an in-
crease in the number of CD3+ cells and in the level of caspase 3-
induced apoptosis in the hepatic metastases of mice that received
the AR71-HisTag clone (Fig 3e and 3f, Fig S3a and S3b),
indicating an inhibition of MIA-induced immunosuppression by
AR71.
These results prompted us to investigate whether the formation
of metastases could also be inhibited by intravenous administration
of AR71. In this experimental setting, wild-type B16 melanoma
cells were used in the hepatic metastasis model, and AR71
(2.5 mg/kg every 24 h) or solvent control was administered
intravenously for 9 days. Histological analysis revealed a
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Figure 1. MIA is functionally active as a dimer. (a) Western blot analysis of MIA in lysates from melanoma tissue (PT: primary tumor; Met:
metastasis) under denaturating conditions. (b) The structure of the MIA dimer according to shape complementarity analyses. The MIA dimer is
characterized by a head-to-tail orientation, with the dimerization domains consisting of the n-Src loop and the cleft next to the distal loop. (c)
Western blot analysis of MIA mutants assessing their ability to form dimers. The first lane shows wt MIA, followed by the D29G/Y69H, V46F/S81P,
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significant reduction in the formation of hepatic metastases upon
treatment with AR71 (Fig 3g and 3h). Increased numbers of
CD3+ cells and activated caspase 3 were detected in the hepatic
metastases of mice treated with AR71 (Fig 3i and 3j, Fig S4a
and S4b).
No adverse effects were observed (data not shown). Although
peptides are generally degraded quickly in vivo by proteases and are
cleared renally, this study demonstrated the potency of AR71 in
suppressing the metastatic spread and immunosuppression of
melanoma cells in vivo.
This study details a two-pronged approach of targeting both the
metastatic spread and immunosuppression of melanoma and
provides a novel leading structure for the design of potent
therapeutics for the treatment of melanoma. Most conventional
treatments still affect fast-dividing cell types in addition to the
cancer cells. There is an urgent need for better targeted therapies.
By targeting MIA, which is only expressed in melanoma and in
differentiating chondrocytes, the adverse reactions of treatment
with MIA inhibitory compounds should be minimal. Side effects
on cartilage are not expected because MIA-deficient mice show
T89P, K91N, G61R, Y30R and R55E mutants. All proteins except for G61R, Y30R and R55E have a clear dimer band. All proteins were electrophoretically
resolved from an RTS expression system by SDS-PAGE. (d) The correlation between dimerization and functional activity revealed that all MIA mutants
capable of dimerization are functionally active in Boyden chamber invasion assays. The G61R, Y30R and R55E mutants which do not form protein
dimers, displayed no MIA-induced effect. (e) NMR structure of MIA showing the dimerization domains and the mutation sites. The dimerization
domains in the n-Src loop and next to the distal loop are depicted in blue and red, respectively. The mutation sites that did not influence dimerization
and functional activity are shown in gray. Residues Y30, R55 and G61 are shown in magenta. This figure was generated using PyMol [27]. (f) Western
blot analysis of MIA and the MIA-homologous MIA2 and TANGO. Only MIA revealed dimerization. (g) Sequence alignment of MIA, the N-terminal part
of MIA2 and TANGO. Conserved cysteines are shown in yellow. Residues important for MIA dimerization are shown in blue and red. The Y30, R55 and
G61 mutation sites are shown in magenta (ns: not significant, *: p,0.05).
doi:10.1371/journal.pone.0037941.g001
Figure 2. Peptide AR71 prevents MIA dimerization. (a) The HTFP assay was used to assess the ability of AR71 to directly interfere with the MIA-
MIA interaction. Fluorescence polarization was normalized (P/P0) to the fluorescence polarization of MIA-Ru(bpy)3 in a well not coated with MIA-
biotin. First, the FP signal of MIA-Ru(bpy)3 was measured in a well that was coated with MIA-biotin and compared to the signal in an uncoated well.
The significant increase in FP in the well coated with MIA-biotin indicates binding of MIA-Ru(bpy)3 to the immobilized MIA-biotin. The binding of
AR71 (1.6 mM) displaced the surface-bound MIA-Ru(bpy)3, as reflected by a decrease in the fluorescence polarization signal. MIA-binding control
peptides 1 and 2 (1.6 mM) did not interfere with the MIA-MIA interaction. (b) Western blot analysis of MIA incubated with AR71 demonstrated
peptide-induced dissociation of the dimer. Control peptides 1 and 2 did not lead to reduced dimer formation. (c) Boyden chamber invasion assays
using Mel-Im cells indicated that AR71 almost completely inhibited MIA activity. Pre-incubation of MIA with AR71 resulted in neutralization of the MIA
effect, while AR71 alone did not influence migratory behavior. The final concentrations were 200 ng/mL for MIA and 1 mM for AR71. (d) The most
significant chemical shift differences projected onto the van der Waals surface of MIA upon titration with AR71 are depicted in red. The binding site is
located in the dimerization domain next to the distal loop (compare to Figure 1e). This figure was generated using PyMol [27]. (ns: not significant, *:
p,0.05).
doi:10.1371/journal.pone.0037941.g002
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Figure 3. Effect of MIA inhibitory peptide AR71 on the formation of metastases in vivo. (a) Immunofluorescence studies of murine B16
melanoma cells stably transfected with an AR71-HisTag construct, with MIA (FITC) shown in green and AR71-HisTag (TRITC) shown in yellow. Co-
localization is depicted in red and is indicated by white arrows. The excess of MIA not co-localized with AR71 is due to the internalization of
exogenous MIA by the melanoma cells [29]. The mock control did not include AR71-HisTag. (b) Murine B16 AR71-HisTag clones were analyzed for
their migratory activity in a Boyden chamber assay. Compared to the mock control, the AR71-HisTag-expressing cell clone displayed drastically
reduced migration by reducing MIA activity. (c) The AR71-HisTag clone and a corresponding mock control were injected into the spleens of Bl/6N
mice (n = 8 each). Histological analysis revealed that AR71-HisTag clones formed significantly fewer hepatic metastases than the mock control cells
did. (d) Representative histological liver sections (upper row) and macroscopic pictures (lower row) of mice injected with the mock control and an
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only minor phenotypic changes [17]. Currently used targeted
melanoma treatment regimes include Vemurafenib which targets
the BRAF V600E mutation and Imatinib which targets activating
c-Kit mutations. Conceptually, a MIA inhibitor would be
beneficial for all melanoma patients since it is not dependent on
mutations which are only present in a subpopulation of patients.
Furthermore, we envision that a MIA inhibitor could be given in
combination with other treatments since it targets a novel pathway
of melanoma progression.
We believe that this study provides an excellent starting point
for the development of a new strategy in melanoma therapy.
Targeting MIA leads to strongly reduced formation of metastases
and immunosuppression and thus provides a new concept for
therapeutic intervention.
Materials and Methods
Cell lines and cell culture conditions
The melanoma cell line Mel-Im, established from a human
metastatic bioptic sample (generous gift from Dr. Johnson,
University of Munich, Germany) was used in all experiments.
Additionally, main experiments were also conducted using the
human cell line Mel-Ju and the murine cell line B16, which were
derived from metastases of malignant melanoma, as well as Mel-
Wei and Mel-Ho cells derived from primary human melanoma.
All cells were maintained in DMEM (PAA Laboratories GmbH,
Co¨lbe, Germany) supplemented with penicillin (400 U/mL),
streptomycin (50 mg/mL), L-glutamine (300 mg/mL) and 10%
fetal calf serum (Pan Biotech GmbH, Aidenbach, Germany) and
split in 1:6 ratio every 3 days.
In vitro spheroid and scratch assays
Spheroid collagen invasion degradation assays were performed
as described previously [18]. Spheroid migration assays were
performed as described [19], except that quantification of
migration was not performed by manual measurements using a
microscope but via the Roche xCELLigence system (Roche,
Mannheim, Germany). Scratch migration assays were performed
as described previously [20]. In all assays, AR71 peptide was used
at a final concentration of 1 mM.
Protein analysis in vitro (Western blotting)
Protein extraction from tumor tissue and Western blotting were
performed as described previously [21,13]. In the multimerization
studies, MIA (1 mg) was incubated with AR71 (2.5 mg) overnight at
RT before being subjected to Western blot analysis. Purified
antibodies which do not detect other MIA isoforms were used
throughout all experiments. MIA mutant expression plasmids
were prepared from the wild type MIA-piVEX2.3-MCS plasmid
[11] by using the QuikChange II Site-Directed Mutagenesis Kit
(Agilent, La Jolla, CA, USA) according to the manufacturer’s
instructions. MIA mutants were expressed using the cell free Rapid
Translation System E. coli HY Disulfide Kit (5Prime, Hamburg,
Germany) as described previously [11].
Boyden Chamber Invasion Assay to determine MIA
activity
Invasion assays were performed in Boyden Chambers contain-
ing polycarbonate filters with 8-mm pore size (Neuro Probe,
Gaithersburg, MD, USA) essentially as de-scribed [11]. MIA was
added to the cell suspension at a final concentration of 200 ng/
mL. Peptide AR71 (sequence: Ac-FHWRYPLPLPGQ-NH2) was
used at a final concentration of 1 mM. Experiments were carried
out in triplicates and repeated at least three times.
Polarization assay setup
Black, streptavidin coated 96 well plates (Greiner Bio-one,
Frickenhausen, Germany) were coated with MIA-biotin as
described and all measurements were performed at RT on a
Polarstar Optima microplate reader (BMG Labtech, Offenburg,
Germany) as described [13]. Briefly, human MIA protein (100 mg)
was labeled with Ru(bpy)3-isothiocyanate (1 mg, Active Motif
Chromeon, Tegernheim, Germany) and purified over a size
exclusion column (Sephadex G75 M PD-10, Amersham Pharma-
cia Biotech, Uppsala, Sweden). After coating with MIA-biotin,
addition of compounds to the well plate was done in the following
order: buffer, peptide, MIA-Ru(bpy)3. A total volume of 250 mL
was used per well. Polarization values are reported relative (P/P0)
to the value of free MIA-Ru(bpy)3 in solution in a well not treated
with MIA-biotin. Reported values represent an average of three
independent measurements.
Cloning Strategy
The Signal-AR71-HisTag pCMX-PL1 expression plasmid was
created by PCR amplification of the human hydrophobic signal-
peptide sequence, responsible for transport into the endoplasmic
reticulum, from a Signal-MIA containing expression plasmid. The
HisTag sequence was inserted at the C-terminal end of the AR71
peptide using the primers 59-GACGAATT-
CATGGCCCGGTCCCTGGTG-39 and 59-GACAAGCTTT-
CAGTGATGGTGATGGTGATGCTGGCCGGGCAAGGG-
CAAGGGGTATCTCCAGTGGAACCTGACAC-
CAGGTCCGGAGAA-39. After amplification of the Signal-
AR71-HisTag fragment, the PCR product was digested with
EcoRI and HindIII (NEB, Frankfurt, Germany). The insert was
purified by gel extraction (Qiagen, Hilden, Germany) and cloned
into the EcoRI and HindIII sites of pCMX-PL1 [22]. The
sequence of the PCR-generated clone was confirmed by DNA
sequencing.
Stable transfection of murine B16 melanoma cells
Stable cell lines expressing AR71-HisTag were generated as
described [14]. After selection of cells comprising antibiotic
resistance we confirmed expression and localization of AR71
peptide on mRNA and protein level by qRT-PCR and
immunofluorescence, respectively.
AR71-HisTag-expressing cell clone, respectively. (e) Anti-CD3 immunohistochemistry revealed an increase in the number of T-lymphocytes in the
livers of mice that received AR71-HisTag-expressing cells. (f) Anti-caspase 3 immunohistochemistry indicated increased caspase 3-mediated apoptosis
in the AR71-HisTag-expressing tumors. (g) Wild-type murine B16 melanoma cells were injected into the spleens of Bl/6N mice before treatment with
i.v. injections of AR71 (n = 8 each). Histological analyses revealed a significant reduction in the average number of hepatic metastases in mice treated
with AR71 as compared to untreated control mice. (h) Representative histological liver sections (upper row) and macroscopic pictures (lower row,
magnifications in lower left corners) of untreated (control) and treated (AR71) mice. (i) Anti-CD3 immunohistochemistry revealed an increase in the
number of T-lymphocytes in the livers of mice treated with AR71. (j) Anti-caspase 3 immunohistochemistry indicated increased caspase 3-mediated
apoptosis in the tumors of mice treated with AR71. (*: p,0.05).
doi:10.1371/journal.pone.0037941.g003
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Recombinant expression of MIA and mutant forms
In vitro protein expression reactions of recombinant human MIA
and its mutants were performed with the Rapid Translation
System RTS 500 E. coli HY Disulfite Kit (Roche, Mannheim,
Germany) according to the manufacturer’s instructions. MIA
mutants were checked for correct folding and function as
described [11].
NMR Spectroscopy
All spectra were recorded at 300 K and pH 7 on a Bruker
DRX600 spectrometer equipped with a pulsed field gradient triple
resonance probe. Water suppression in experiments recorded on
samples in H2O was achieved by incorporation of a Watergate
sequence into the various pulse sequences [23,24]. 2D 1H-15N
HSQC spectra with reduced signal loss due to fast exchanging
protons were recorded using procedures described previously [25].
All spectra were processed with NMRPipe and analyzed with
NMRView [26]. Data handling was performed with NMRView.
Structure visualisation and superimpositions were done with the
PyMol software [27].
Dimer model
The PreBI modeling software (http://pre-s.protein.osaka-u.ac.
jp/prebi/) was used together with the published X-ray structure of
MIA (PDBid: 1I1J) for the prediction of the putative dimer
interface. Employing the monomeric NMR structure of MIA
(PDBid: 1HJD) together with the interface information obtained in
the previous step a three-dimensional model of the dimeric
complex was calculated. Computations were performed using the
data driven protein-protein docking program HADDOCK [10].
Protein binding studies
The NMR titration of MIA with AR71 consisted of monitoring
changes in chemical shifts and line widths of the backbone amide
resonances of uniformly 15N-enriched MIA samples as a function
of ligand concentration [28].
In vivo metastasis assay
To determine the effect of peptide AR71 on the metastatic
potential of murine B16 melanoma cells in vivo, a previously
developed mouse metastases model was used [16]. 16105 cells (in
50 ml) of the AR71-HisTag expressing B16 cell clone AR71-
HisTag or the corresponding mock control cells were injected into
the spleen of syngeneic Bl/6N mice (n = 8 each). After nine days
the mice were sacrificed, the livers were resected and the number
of visible black tumor nodules on the surface of the livers was
documented. Tissues were fixed in formalin, and afterwards,
paraffin embedded sections were hematoxylin and eosin stained
for histological analysis.
In a second experimental setting, 16105 wt mouse melanoma
B16 cells suspended in a solution containing AR71 (1 mg/mL) and
0.9% NaCl (or only 0.9% NaCl in the control group) were injected
in 50 ml into the spleen of Bl/6N mice (n = 8 each group). Peptide
AR71 was injected i.v. (2.5 mg/kg in 50 mL every 24 h). After nine
days, the mice were sacrificed and the livers were resected. Also
here, formation of tumor nodules was documented. Following
fixation with formalin and paraffin embedding, hematoxylin and
eosin stained sections for histological analysis were generated.
Immunohistological stainings were performed using routine
diagnostic procedures and anti-CD3 (#RM-9107, NeoMarkers,
Fremont, California) and anti-Caspase 3 (#9661, Cell Signaling,
Frankfurt, Germany) antibodies. For quantification of immuno-
histological stainings, livers from every mouse per group were
evaluated.
Immunofluorescence assays
Cells were grown in a 4-well chamber slide (BD Bioscience,
Heidelberg, Germany) for 48 h and fixed using 4% paraformal-
dehyde in 0.1 M phosphate-buffered saline (PBS) for 15 min. After
permeabilization of cells and blocking of non-specific binding sites
(1% BSA/PBS, 1 h, 4uC) cells were incubated with primary
antibodies rabbit anti-MIA (Biogenes, Berlin, Germany) and
mouse anti-HisTag (BD Bioscience) at a concentration of 1 mg/
mL at 4uC for 2 h. After washing steps, secondary antibodies
TRITC anti-mouse (1:200, Jackson Immuno Research Laborato-
ries, West Grove, PA, USA) and FITC anti-rabbit (1:200,
DakoCytomation, Hamburg, Germany) were added. Following
incubation with secondary antibodies, cells were washed with PBS
and coverslips were mounted on slides using Hard Set Mounting
Medium with DAPI (Vectashield, H-1500, Linearis, Wertheim
Germany) and imaged using an Axio Imager Zeiss Z1 fluorescence
microscope (Axiovision Rel. 4.6.3) equipped with an Axio Cam
MR camera. Images were taken using 63x oil immersion lenses.
Statistical analysis
Results are expressed as mean 6 S.E.M. or percent. Compar-
ison between groups was made using the Student’s unpaired t-test.
A p-value ,0.05 was considered as statistically significant (ns: not
significant, *: p,0.05). All calculations were made using the
GraphPad Prism Software (GraphPad Software, Inc., San Diego,
USA).
Supporting Information
Figure S1 Species conservation of MIA and in vitro
inhibition by AR71. (a) The MIA protein sequence is highly
conserved throughout various species. All four cysteines (orange)
and Y30 and R55 (green) are completely conserved. G61
(magenta) is mostly conserved; Salmo salar and Danio rerio have an
alanine at position 61; alanine has electrostatic properties similar
to those of glycine. (b) Additional functional assays were
performed (I: collagen invasion assay; II: Scratch Assay, III:
Spheroid migration assay) to confirm the inhibitory effects of
AR71 on melanoma cell migration and invasion in two melanoma
cell lines (Mel-Im, Mel-Ju).
(TIF)
Figure S2 Native PAGE analysis of MIA incubated with
AR71 demonstrated peptide-induced dissociation of the
MIA dimer.
(TIF)
Figure S3 Immunohistochemical evaluation of murine
tissues. (a) Representative CD3-stained liver sections of mice
treated with B16 mock or B16 AR71-HisTag cells. (b) Represen-
tative caspase 3-stained liver sections from mice treated with B16
mock or B16 AR71-HisTag cells. Scale bars are 100 mm.
(TIF)
Figure S4 Immunohistochemical evaluation of murine
tissues. (a) Representative CD3-stained liver sections from
solvent control and AR71-treated mice. (b) Representative caspase
3-stained liver sections from solvent control and AR71-treated
mice. Scale bars are 100 mm.
(TIF)
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